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Background: This study aimed to assess: 1) vaccine hesitancy (VH) prevalence among French general prac-
titioners (GPs) through the frequency of their vaccine recommendations, and 2) the determinants of these
recommendations.
Methods: Cross-sectional observational study in 2014 nested in a national panel of 1712 randomly selected
GPs in private practice in France. We constructed a score of self-reported recommendation frequency for 6
speciﬁc vaccines to target populations.
Results: 16% to 43% of GPs sometimes or never recommended at least one speciﬁc vaccine to their target
patients. Multivariable logistic regressions of the dichotomized score showed that GPs recommended vac-
cines frequently when they felt comfortable explaining their beneﬁts and risks to patients (OR = 1.87;
1.35–2.59), or trusted ofﬁcial sources of information highly (OR = 1.40; 1.01–1.93). They recommended
vaccines infrequently when they considered that adverse effects were likely (OR = 0.71; 0.52–0.96) or
doubted the vaccine's utility (OR = 0.21; 0.15–0.29).
Interpretation:Our ﬁndings show that after repeated vaccine controversies in France, some VH exists among
French GPs, whose recommendation behaviors depend on their trust in authorities, their perception of the
utility and risks of vaccines, and their comfort in explaining them. Further research is needed to conﬁrm
these results among health care workers in other countries.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past two decades several vaccine controversies have
emerged in various countries, including France, inducing worries
about severe adverse effects and eroding conﬁdence in health authori-
ties, experts, and science (Larson et al., 2011). These two dimensions
are at the core of the vaccine hesitancy (VH) observed in the general
population. VH is deﬁned as delay in acceptance of vaccination, or
refusal, or even acceptance with doubts about its safety and beneﬁts,
with all these behaviors and attitudes varying according to context,
vaccine, and personal proﬁle, despite the availability of vaccine servicessanté, 23 rue Stanislas Torrents,
. This is an open access article under(SAGE Group 2014) (Larson et al., 2014; Dubé et al., 2013). VH presents
a challenge to physicians who must address their patients' concerns
about vaccines and ensure satisfactory vaccination coverage.
Physicians, and especially general practitioners (GPs), are the
cornerstone of vaccination implementation in most countries and
their recommendations play an inﬂuential role in their patients' vaccine
behavior (Gust et al., 2008; Freed et al., 2011; Schwarzinger et al., 2010).
In France, GPswrite prescriptions for 90% of the vaccinations purchased.
Patients may return to the GP for administration after purchasing the
vaccine, but they may also see a nurse or make other arrangements or
fail to follow up (Ecole des Hautes Etudes en Santé Publique, 2013).
Although physicians are generally favorable to vaccination, some, espe-
cially thosewhose practice includes but is not limited to homeopathy or
acupuncture, are known to be negative toward vaccination in general or
toward some particular vaccines (Benin et al., 2006; Pulcini et al., 2013;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Social, demographic, and professional characteristics of the study population (French
nationwide panel of general practitioners, unweighted data).
No. (%) Refusals
(n = 2012)
Panel
participants
(n = 1712)a
Survey
participants
(n = 1582)
Stratiﬁcation variables
Gender
Male 1482
(73.7)
1100 (64.3b) 1014 (64.1)
Female 530 (26.3) 612 (35.7) 568 (35.9)
Age — years
b50 559 (27.8) 618 (36.1b ) 580 (36.7)
50–58 732 (36.4) 622 (36.3) 573 (36.2)
N58 721 (35.8) 472 (27.6) 429 (27.1)
GPs density of the municipality
of practice
b−19.3% of national average 601 (29.9) 511 (29.8) 474 (30.0)
Between−19.3% and +17.7%
of national average
957 (47.5) 818 (47.8) 753 (47.6)
N+17.7% of national average 454 (22.6) 383 (22.4) 355 (22.4)
2012 workload
b3067 procedures 369 (18.3) 349 (20.4c) 318 (20.1)
3067–6028 procedures 953 (47.4) 854 (49.9) 793 (50.1)
N6028 procedures 690 (34.3) 509 (29.7) 471 (29.8)
Practice population characteristicsd
Proportion of patients aged under 16
(%)
[0–16] – 371 (23.9) 333 (23.3)
[17–21] – 387 (24.9) 353 (24.7)
[22–25] – 402 (25.9) 380 (26.6)
[26–50] – 393 (25.3) 364 (25.5)
Proportion of patients aged over 70 (%)
[0–8] – 459 (29.6) 422 (29.5)
[9–12] – 391 (25.2) 361 (25.2)
[13–17] – 361 (23.3) 335 (23.4)
[18–67] – 342 (22.0) 312 (21.8)
Professional characteristics
Practice
Group – 1002 (58.5) 929 (58.7)
Solo – 710 (41.5) 653 (41.3)
Occasional practice of alternative medicinee
No – 1511 (88.3) 1403 (88.7)
Yes – 201 (11.7) 179 (11.3)
a Chi-square test: refusals vs participants in the panel.
b P ≤ .001.
c P ≤ .05.
d Quartiles; 159 missing values.
e Alternative medicine: homeopathy and/or acupuncture.
892 P. Verger et al. / EBioMedicine 2 (2015) 891–897François et al., 2011). Moreover, the percentage of physicians reporting
doubts about the harmlessness of vaccines is growing (Dubé et al.,
2013). Physicians may therefore share some of the same questions
and concerns expressed by the general population (Poland, 2010)
and distrust health authorities, just as the population does (Yaqub
et al., 2014). These ﬁndings raise the question of whether doubts
about vaccine safety and distrust of the health authorities might
fuel VH among physicians. Vaccine-hesitant physicians are likely to
recommend vaccines to their patients at lower rates and with less
conviction than nonhesitant physicians (Dubé et al., 2013; Bean and
Catania, 2013).
As part of a national panel of 1712 GPs in private practice in France,
we conducted a study of this topic with two main objectives. First, we
sought to assess the presence, extent, and variability of VH among
FrenchGPs, in relation to six vaccine situations (speciﬁc vaccine and tar-
get population) with suboptimal vaccination coverage: we assessed
their VH through their self-reported recommendation behavior. Second,
we sought to test factors associated with GPs' vaccine recommenda-
tions, after verifying that their recommendations were correlated to
their own vaccination behavior. Several speciﬁc vaccines are or have
been controversial in France: questions have been raised about the
safety and beneﬁts of vaccines against hepatitis B, HPV and seasonal in-
ﬂuenza, as well as against adjuvants (Appendix, Table A1), and about
the reliability of the information disseminated by health authorities
about them. Other vaccines remain uncontroversial, including MMR
(perhaps surprisingly) and the vaccine against meningococcalmeningi-
tis C. We expected that GPs' beliefs about vaccine utility in general and
their self-efﬁcacy — beliefs in their ability to convince patients to be
vaccinated (Bandura, 1994) — would be positively correlated to their
recommendation of all vaccines, either controversial or not (hypothesis
1). On the other hand, we also expected that GPs' beliefs about vaccine
safety and trust in health authorities would be negatively correlated to
their recommendations for controversial, but not for uncontroversial,
vaccines (hypothesis 2).
2. Methods
2.1. Population
The panel was designed to collect data regularly about GPs' medical
practices, working conditions, and opinions about public health reg-
ulatory policies and was set up following the methods used for a pre-
vious panel (Verger et al., 2012). Enrolment took place between
November 2013 andMarch 2014: we selected GPs in private practice
(non-salaried) by random sampling from the Ministry of Health's
exhaustive database of health professionals in France (“Répertoire
Partagé des Professionnels de Santé”). Sampling was stratiﬁed for
sex, age (tertiles in the sampling base: b50, 50–58, N58 years), and
annual number of ofﬁce consultations and house calls (workload), ob-
tained from the exhaustive reimbursement database of the National
Health Insurance Fund for each GP in 2012. Samplingwas also stratiﬁed
for the density of each GP's municipality of practice. The sample size
was set so that the smallest stratum resulting contained at least 10
GPs. Agreement to participate in the panel meant agreeing to respond
to a cross-sectional survey every six months for two and a half years.
GPs planning to retire within 6 months or who practiced acupuncture
or homeopathy or other alternative medicine exclusively were exclud-
ed. To limit any selection bias that might have resulted from particular
opinions or attitudes, the speciﬁc topics to be studied were not
mentioned to GPs before they were asked to participate. The National
Authority for Statistical Information (Commission Nationale de
l'Information Statistique) approved the panel.
The ﬁrst cross-sectional survey in this panel focused on vaccination
behaviors and attitudes and took place from April to July 2014. GPs
received a compensation equivalent to one consultation fee for their
participation in this survey.2.2. Procedure and Questionnaires
Professional investigators ﬁrst contacted GPs to ask them to partici-
pate, obtain their consent, and verify inclusion criteria; they then con-
ducted the inclusion interview, with computer-assisted telephone
interview (CATI) software. The interview included a short standardized
questionnaire collecting information about participants' professional
characteristics (Table 1). In the second step, participants received
written consent forms to return to us.
We developed a standardized questionnaire for the ﬁrst cross-
sectional interview after reviewing the literature, conducting qualita-
tive interviews on the topic with 10 GPs, and discussing it with experts.
We pilot-tested the questionnaire for clarity, length, and face validity
among 50 GPs and modiﬁed several questions found to be unclear.
As summarized in Table 2, the questionnaire collected information
about: 1) the frequency atwhichGPs recommended vaccines in six spe-
ciﬁc situations, chosen because their current coverage in France does
not meet ofﬁcial objectives; 2) GPs' opinions about the likelihood of
links between potential severe adverse effects and certain vaccines or
vaccine components (adjuvants) that have been or still are the subject
of public and/or scientiﬁc debate in France or elsewhere (six items);
3) GPs' beliefs about the utility of vaccines; 4) GPs' conﬁdence in their
Table 2
Practices, opinions, and attitudes of GPs regarding vaccination (weighted data, N = 1582).
Frequency of vaccine recommendations (line %) Never Sometimes Often Always
MMR to non-immune adolescents and young adults 4.3 12.9 22.9 59.9
Meningococcal meningitis C to ages 2–24 (catch-up)a 17.6 25.7 23.4 33.3
Meningococcal meningitis C to 12-month-old infants 15.7 16.7 15.9 51.7
Human papilloma virus vaccine to girls aged 11–14b 10.5 17.2 26.8 45.6
Hepatitis B to adolescents (catch-up) 10.9 26.0 29.1 34.0
Seasonal inﬂuenza to adults under 65 with diabetes 4.5 11.6 26.2 57.6
Trust in the reliability of information provided by ofﬁcial sources about vaccination (line %) No trust Distrust somewhat Somewhat trust Strong trust
Ministry of Healthb 5.7 13.3 55.1 25.9
Public health agencies 2.8 8.8 57.1 31.3
Scientiﬁc sources 1.7 3.6 48.3 46.4
Specialist colleagues 3.4 5.4 52.0 39.3
Perceived likelihood of links between speciﬁc vaccines and potential severe adverse effects
(line %)
Not at all likely Not very likely Somewhat likely Very likely
Seasonal inﬂuenza vaccine & Guillain–Barré syndromea 21.5 54.2 20.5 3.8
Hepatitis B vaccine & multiple sclerosis 48.1 40.3 9.2 2.5
Aluminum adjuvants & Alzheimer's disease 38.4 50.0 8.7 2.9
AS03-adjuvanted 2009 A/H1N1 vaccine (Pandemrix) & narcolepsya 29.7 49.1 16.5 4.8
Human papilloma vaccine & multiple sclerosis 51.3 43.3 4.5 0.9
Vaccines containing adjuvant & long-term complications 18.4 48.8 26.3 6.5
Perceptions of vaccines utility (line %) Strongly
disagree
Somewhat disagree Somewhat agree Strongly
agree
Today some vaccines recommended by authorities are not usefulb 38.3 35.3 20.0 6.4
Children are vaccinated against too many diseasesb 53.1 26.7 14.6 5.5
Self-efﬁcacy: conﬁdence in one's ability to explain vaccines (line %) Very
unconﬁdent
Somewhat
unconﬁdent
Somewhat
conﬁdent
Very
conﬁdent
Vaccine utility 0.9 2.9 41.7 54.5
Vaccine safetya 2.2 15.8 55.7 26.2
Role of adjuvants 11.1 45.7 32.2 11.0
Abbreviations: MMR, measles, mumps and rubella.
a One missing value.
b Two missing values.
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vants to their patients (as a proxy for self-efﬁcacy in explaining vaccina-
tion to patients); and 5) GPs' trust in the reliability of various sources of
information about vaccine beneﬁts and risks. For all of these items, we
collected answers with 5-point Likert scales that included a “no
opinion” answer.
In addition, participants were asked about their own vaccinations
(2013–2014 seasonal inﬂuenza and hepatitis B), whether they had
had any patients in the past ﬁve years with any of the following
vaccine-preventable diseases (VPDs): measles, acute or recently
diagnosed chronic hepatitis B, bacterial meningitis, cervical cancer, or a
hospital admission for a complication of seasonal inﬂuenza. Finally, they
were asked if they had attended any continuous medical education
(CME) courses on infectious diseases andvaccination in theprevious year.
2.3. Statistical Analysis
Tomatch the sample more closely to the national French GP popula-
tion for the stratiﬁcation variables, we weighted the data with SURVEY
procedures (PROC SURVEYFREQ, PROC SURVEYLOGISTIC, SAS 9.4 statis-
tical software).
We constructed two dependent variables by summing GPs' re-
sponses on the Likert scales to the corresponding items to calculate: a
global score of the reported frequency of their vaccine recommenda-
tions to patients (“global score of vaccine recommendations”; six
items; the lower the score the most likely they were to be vaccine-
hesitant); and a subscore for the frequency of their recommendations
of vaccines that are not controversial in France (MMR, meningococcal
meningitis C in infants and in young adults; three items); we dichoto-
mized these two scores at the median.Finally, we constructed four explanatory variables of interest: one
summing GPs' opinion of the likelihood of speciﬁc potential severe
adverse effects for each of six vaccines (“perceived vaccine adverse
effects”, six items); a score of “doubts about vaccine utility” (two
items); a proxy score for GPs' self-efﬁcacy regarding their ability to ex-
plain the beneﬁts and risks of vaccines to their patients (“self-efﬁcacy”,
three items); and a score of GPs' trust in the reliability of information
provided by ofﬁcial sources about these beneﬁts and risks (“trust in
ofﬁcial sources”, four items). We categorized these four explanatory
variables by their quartiles.
For all six scores (the two dependent and four explanatory
variables), we calculated Cronbach's alpha coefﬁcients to measure
their internal consistency (Bland and Altman, 1997; Tavakol and
Dennick, 2011): Internal consistency was considered satisfactory at
values of 0.7 b alpha b 0.8 and acceptable at values of 0.6 b alpha b 0.7
(Table A2, Appendix). Principal component analyses conﬁrmed the uni-
dimensionality of each score (Table A2, Appendix).
We used a multivariable logistic regression adjusted for the stratiﬁ-
cation variables to test the association between the dichotomized global
score of vaccine recommendations and GPs' own vaccinations
(2013–2014), seasonal inﬂuenza (yes or no), hepatitis B (3 doses or
more or fewer than 3 doses or none). We also used multivariable lo-
gistic regressions to test associations between the two dependent
variables and the four variables of interest, adjusting the models
for the stratiﬁcation variables, GPs' professional characteristics, and
the number of different vaccine-preventable diseases in the practice
(Table 3).
We computed the variance inﬂation factor (VIF) to test for
multicollinearity in equivalent linear models and interpreted VIF values
b5 as presenting no multicollinearity issues (Rogerson, 2001). To test
Table 3
Factors associated with vaccine recommendationsa by GPs (logistic regressions, weighted data, N = 1572b).
Explanatory variables Global score (ref. b19) Subscore for uncontroversial vaccines
(ref. b9)
Univariable
regression
Multivariable
regression
Univariable
regression
Multivariable
regression
ORa [95% CI]
Stratiﬁcation variables
Gender (ref. male)
Female 1.38 [1.13;1.68] 1.53 [1.19;1.96] 1.69 [1.37;2.09] 1.73 [1.33;2.26]
Age, years (ref. b50)
50–58 0.68 [0.55;0.86] 0.79 [0.61;1.03] 0.51 [0.40;0.65] 0.57 [0.43;0.76]
N58 0.52 [0.41;0.66] 0.64 [0.48;0.86] 0.34 [0.26;0.43] 0.41 [0.30;0.55]
2012 workload (ref. b3067 procedures)
3067–6028 procedures 1.98 [1.54;2.55] 1.56 [1.17;2.07] 1.78 [1.39;2.28] 1.42 [1.05;1.92]
N6028 procedures 2.18 [1.64;2.89] 1.81 [1.30;2.52] 2.04 [1.54;2.71] 1.86 [1.31;2.64]
GPs density of municipality of practice (ref. b−19.3% of the national average)
Between−19.3% and +17.7% of the national average 0.99 [0.79;1.24] 0.89 [0.69;1.15] 1.18 [0.93;1.48] 1.11 [0.85;1.44]
N+17.7% of the national average 0.88 [0.67;1.14] 0.86 [0.63;1.16] 1.02 [0.78;1.33] 1.03 [0.75;1.41]
Professional characteristics
Occasional practice of alternative medicinec (ref. no)
Yes 0.27 [0.19;0.37] 0.47 [0.33;0.67] 0.30 [0.22;0.41] 0.52 [0.37;0.73]
CME on infectious diseases and vaccination in 2013 (ref. no)
Yes 1.56 [1.28;1.90] 1.24 [1.00;1.55] 1.56 [1.27;1.92] 1.23 [0.97;1.55]
Number of different VPDs among GPs' patients [0–5] 0.79 [0.73;0.86] 1.12 [1.01;1.23] 0.81 [0.74;0.88] 1.05 [0.96;1.16]
Conﬁdence scoresd
Self-efﬁcacy: conﬁdence in one's ability to explain vaccines (ref. low ([3;7]))
Medium ([8;9]) 1.94 [1.47;2.55] 1.45 [1.08;1.96] 1.75 [1.33;2.30] 1.37 [1.01;1.86]
High ([10;12]) 2.70 [2.02;3.61] 1.87 [1.35;2.59] 2.02 [1.51;2.70] 1.50 [1.07;2.09]
Trust in ofﬁcial sources about vaccination (ref. low ([4;11]))
Medium ([12;13]) 1.89 [1.44;2.49] 1.20 [0.88;1.63] 1.89 [1.44;2.47] 1.16 [0.86;1.59]
High ([14;16]) 3.04 [2.28;4.04] 1.40 [1.01;1.93] 2.98 [2.24;3.98] 1.35 [0.96;1.89]
Scores of perception of vaccine risk and utilityd
Perception of potential severe adverse effects (ref. low ([6;9]))
Medium ([10;12]) 0.66 [0.51;0.85] 0.74 [0.56;0.99] 0.71 [0.54;0.94] 0.76 [0.56;1.03]
High ([13;24]) 0.38 [0.29;0.49] 0.71 [0.52;0.96] 0.42 [0.32;0.55] 0.77 [0.55;1.07]
Doubts about vaccine utility (ref. low (2))
Medium ([3;4]) 0.57 [0.44;0.73] 0.66 [0.51;0.86] 0.54 [0.41;0.71] 0.59 [0.44;0.80]
High ([5;8]) 0.13 [0.09;0.17] 0.21 [0.15;0.29] 0.13 [0.10;0.18] 0.20 [0.14;0.28]
Nagelkerke R2 0.25 0.26
Abbreviations: ORa, adjusted odds-ratio; CI, conﬁdence interval; CME, continuing medical education; VPD, vaccine-preventable disease.
Self-efﬁcacy: the higher the score, the more self-efﬁcacious GPs feel about their ability to explain the beneﬁts and risks of vaccines to their patients.
Trust in ofﬁcial sources about vaccination: the higher the score, the more trust GPs have in the reliability of information provided by ofﬁcial sources about vaccines' beneﬁts and risks.
Perception of potential severe adverse effects: the higher the score, the more GPs consider that links between six vaccines and speciﬁc potential severe adverse effects are likely.
Doubts about vaccine utility: the higher the score, the greater the doubts GPs express about vaccine utility.
a Both scores dichotomized at the median.
b 10 missing values.
c Homeopathy and/or acupuncture.
d All scores constructed by summing the responses to the Likert scales of the corresponding items (see Table 2 for details); they were then categorized according to quartiles
(Q1, Q2–3, Q4).
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participants might have biased the estimations of the regression analy-
ses, we implemented a bivariate probit model with sample selection
(which makes it possible to test for the presence of selection bias and
to correct it, see the Appendix for a further explanation of this model)
(Heckman, 1979; Greene, 2003; Obrizan, 2010). The likelihood-ratio
(LR) test of independent equations was used to test the null hypothesis
of no correlation between error terms from each equation. Finally, to
verify the robustness of our results, we conducted sensitivity analyses
with a dichotomization threshold at the mean + 1 standard deviation
for the vaccine recommendation scores.
All analyses were based on two-sided P-values, with statistical sig-
niﬁcance deﬁned by P ≤ 0.05. They were conducted with SAS 9.4 statis-
tical software (SAS Institute, Cary, NC).2.4. Funding
The study was funded by the Direction de la Recherche, des Etudes,
de l'Evaluation et des Statistiques (DREES)/Ministère des affairessociales et de la santé and the Institut National de Prévention et
d'Education pour la Santé (INPES). This research has also separately
beneﬁted from the joint assistance of the French National Health Insur-
ance Fund for Employees (CNAMTS), the French Directorate General of
Health (DGS), the Arc Foundation for Cancer Research, the French Na-
tional Cancer Institute (INCa), the French National lnstitute for Preven-
tion and Education in Health (INPES), the French National Institute of
Health andMedical Research (INSERM), the French InterDepartemental
Agency for the Fight against Drugs and Addictive Behaviors (Mildeca)
and the French Social Security Scheme for Liberal Professionals (RSI)
as part of the "Primary Prevention" call for proposals issued by IReSP
and INCA in 2013.3. Results
Of the 5151 randomly selected GPs invited to participate in the
panel, 695 could not be contacted, and 732 were not eligible; 1712/
3724 eligible GPs (46.0%) agreed to participate. GPs who refused were
more often men (P b 10−3), older (P b 10−3), and had more
895P. Verger et al. / EBioMedicine 2 (2015) 891–897consultations in 2012 (P b 0.05, Table 1). They reported two main rea-
sons for refusing: lack of time (55%) and lack of interest in participating
in a panel (31%). In all, 1582/1712 GPs (92.4%) participated in the cross-
sectional survey: their characteristics did not differ signiﬁcantly from
those of the GPswho joined the panel but did not participate in the vac-
cination survey (Table 1).
The frequency of GPs' vaccine recommendations to their patients
varied according to the vaccine situation (Table 2): 83% of the partici-
pants reported that theywould often or always recommend vaccination
against measles, mumps and rubella (MMR) for non-immune adoles-
cents and young adults, 68%would recommend vaccination againstme-
ningococcal meningitis C for infants aged 12 months, but only 57% for
the group aged 2–24 years (Table 2). Over 80% of the participants
trusted ofﬁcial sources (Ministry of Health, health agencies, scientists,
or specialist colleagues) to provide reliable information about vaccine
beneﬁts and risks (Table 2). GPs' opinions of the likelihood of severe
adverse effects of vaccines also varied according to vaccine: 6% of the
participants considered a link between HPV vaccines and multiple
sclerosis likely or very likely, while 33% responded positively to the
question about a link between adjuvanted vaccines and long-term com-
plications. More than a quarter (26%) agreed somewhat or strongly that
some vaccines recommended by the authorities are not useful and 20%
that children are vaccinated against too many diseases. Only 43% of the
participants felt conﬁdent explaining the role of adjuvants to their
patients (Table 2).
Overall, 89% of the participants reported that at least one of their
patients had had at least one of the vaccine-preventable diseases men-
tioned in the questionnaire in the past 5 years.
Multivariable logistic regressions of the dichotomized global score
of vaccine recommendations (Table 3) showed that GPs' vaccine
recommendations to patients were more frequent when they were
comfortable explaining beneﬁts and risks to patients, or trusted ofﬁcial
sources of information highly thanwhen they did not. Their recommen-
dationswere less frequentwhen they believed serious adverse effects to
be likely, or doubted the vaccine's utility than when they did not.
Looking at the dichotomized subscore for recommendations of un-
controversial vaccines, we found results similar to those for the global
score, above, for comfort in ability to explain beneﬁts and risks and for
doubts about vaccine utility. On the other hand, trusting ofﬁcial sources
about vaccination and opinions about potential severe adverse effects
were not associated with this subscore.
We found no issue of multicollinearity in the linear models and, as
multicollinearity is a property of the explanatory variables, not the
dependent variable (Allison, 2012), we can conclude that there was
no issue of multicollinearity in the logistic models either. The results
of the LR tests for the bivariate probit model with sample selection
showed no signiﬁcant correlation for either recommendation score
(global score: rho= 0.05, P= 0.97; score for uncontroversial vaccines:
rho=0.18; P=0.89). Dichotomization of the scoreswith a threshold at
mean+ 1 standard deviation rather than the median produced similar
estimates of the odds ratios for the variables of interest. The multivari-
able logistic regression of the dichotomized global score of vaccine rec-
ommendations, adjusted for the four stratiﬁcation variables, showed
that GPs' recommendations to patients were signiﬁcantly associated
with their own vaccination behavior (2013–2014 seasonal inﬂuenza:
ORa = 2.95, 95% CI = [2.31;3.77]; 3 doses or more of hepatitis B
vaccine: 1.90 [1.27;2.84]).
4. Discussion
Our study addresses the attitudes and behaviors of a large national
sample of GPs regarding several vaccines and target populations.
Although their self-reported vaccine recommendations to their patients
varied substantially according to the situation, these recommendations
were nonetheless somewhat consistent. Theyweremore consistent and
frequent when GPs were comfortable in their ability to explain thebeneﬁts and risks of vaccines and when they trusted ofﬁcial sources of
information highly; they were less consistent and less frequent for
GPs who expressed doubts about the harmlessness and, above all, the
utility of some recommended vaccines. On the contrary, however, for
the vaccines against meningitis C and MMR, that is, vaccines which
are not controversial in France (see Appendix, Table A1), the frequency
of GPs' recommendations was no longer associated with either trusting
ofﬁcial sources of information or expressing doubts about harmlessness.
Given that by joining the panel, GPs agreed to take part in ﬁve differ-
ent surveys during a 30-month period, the commitment rate (46%) was
high, higher than in other primary physician panels (Joyce et al., 2010).
To limit potential selection bias that could have resulted from particular
opinions or attitudes about vaccination, this topic was notmentioned to
GPs before they were asked to consent to participate in the panel. Panel
participants differed from non-participants for several characteristics
(sex, age and workload), and these characteristics were associated
with the vaccine recommendation scores (Table 3). But weighting the
sample according to sex, age and workload should have corrected this
selection bias and prevented any impact on the recommendation scores.
Moreover, the lack of signiﬁcance of the LR tests for the bivariate probit
models with sample selection gives us conﬁdence that the estimates of
the logistic regression models were not biased.
Vaccine recommendation behaviors were self-reported, which is a
limitation of our study: declaration or desirability biases cannot be
excluded. However, questionnaire data appears to overestimate vacci-
nation rates by less than 10% (Brien et al., 2012), and self-reported pan-
demic or seasonal inﬂuenza vaccination coverage in hospital healthcare
workers has been shown to be a good proxy for recorded vaccine cover-
age (Llupià et al., 2012). Validating the self-reported data by retrieving
reliable information about GPs'behaviors from patients' ﬁles was not
feasible, even for a limited sample of GPs, especially as very few GPs in
private practices consistently record data about patients and consulta-
tions. The Cronbach alpha of the scores for vaccine recommendations
(0.74 and 0.63) and principal component analyses conﬁrmed the inter-
nal validity of the scores.
Moreover, several reasons indicate that these scores are better prox-
ies for VH than the separate study of each vaccine situation separately.
First, the notion of VH is deﬁned by a variety of behaviors and attitudes
toward different vaccine situations, not by a single, unidimensional
approach of opposition (Larson et al., 2014; Dubé et al., 2013). Second,
GPs' self-reported recommendation frequency may also reﬂect in part
the degree to which they are favorable to vaccines (Larson et al., 2014;
Peretti-Watel et al., 2015). Finally, the strong association between the
recommendation scores and GPs' own vaccination behavior scores
conﬁrms the robustness of the global score as a proxy for VH.
Two ﬁnal weaknesses must be noted. Because this vaccination sur-
vey is cross-sectional and retrospective, no causal inferences can be
drawn. In addition, because VH depends highly on context, it is possible
that our results cannot be extrapolated to other countries, where no or
different vaccine controversies have occurred (Larson et al., 2014).
There are fewpublished studies of GPs' vaccine recommendation be-
havior for most of the situations examined in our study. In France,
François et al. found that 14% of GPs never or sometimes recommend
hepatitis B vaccines to adolescents (37% in our study) (François et al.,
2011). In Minnesota, McRee et al. found that 24% of health care pro-
viders most often do not recommend HPV vaccines to young girls
(28% in our study) (McRee et al., 2014). Our ﬁndings show thatGPs' vac-
cine recommendations vary according to the vaccine situation and thus
suggest that VH is prevalent among French GPs. The recommendation
scores allowed us to capture this hesitancy. GPs' VH may contribute to
the suboptimal vaccine coverage for the vaccines and target groups
considered in this study. The absence of physicians' recommendations
has been reported as an important reason for non-vaccination against
various vaccine-preventable diseases (Schwarzinger et al., 2010;
Holman et al., 2014; Zimmerman et al., 2003). Hesitant physicians
are less likely to try to convince hesitant or reluctant patients to be
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all — patients' questions about vaccination safety and risks of
contracting illnesses, the two reasons patients give most frequently for
their own VH (Yaqub et al., 2014).
Our ﬁndings shed light on reasons for VH among GPs. Consistent
with our ﬁrst hypothesis, doubts about the utility of certain vac-
cines, and lack of self-efﬁcacy, both of which probably reﬂect GPs'
enduring beliefs and attitudes, were associated with the global vac-
cine recommendation score and the subscore. Distrust of health au-
thorities and experts and a perception of severe adverse effects of
vaccines — both variables related to the existence of past and
ongoing controversies — were not associated with uncontroversial
vaccines but only with the global score. This ﬁnding conﬁrms our
second hypothesis.
Previous results in France and elsewhere have reported prevalence
rates of doubts about vaccine utility ranging between 22% and 37%
among physicians (Dubé et al., 2013; François et al., 2011; Bruno et al.,
2014). Our ﬁndings suggest that such doubts are a stronger factor in
GPs' VH than is their perception of side effects. These doubts may also
be linked to a tendency of some GPs to criticize ofﬁcial recommenda-
tions and guidelines, for example, because they consider them too
constraining and ill adapted to the reality of practice and patients
(Clerc et al., 2011). GPs often identify the complexity of the vaccine
schedule and its annual modiﬁcations for new vaccines and new guide-
lines as constraints (Larson et al., 2011; François et al., 2011).
The directions of the links observed between GPs' self-efﬁcacy level
in explaining the beneﬁts and risks of vaccines or the role of adjuvants
and their global vaccine recommendation score (as well as the subscore
for uncontroversial vaccines) could not be disentangled in this cross-
sectional study. GPs' lack of self-efﬁcacy may contribute to their VH,
which in turn could also reduce their self-efﬁcacy. This self-efﬁcacy
may be affected by the paucity of initial training in the ﬁeld of vaccina-
tion (Yaqub et al., 2014; Cabana et al., 1999; Pulcini et al., 2014), which
does not prepare them for the new challenges of communication with
patients in contemporary societies (Edwards et al., 2002).
Few studies have addressed GPs' trust toward various stakeholders
when studying their vaccination behaviors (Bish et al., 2011). Only ami-
nority of GPs strongly trusted health authorities and public health agen-
cies, and distrust toward themwas not infrequent. These ﬁndings were
contrary to those about GPs' attitudes regarding scientiﬁc sources
(Table 2). Our results suggest that low or moderate trust in health
authorities and experts (Table 3) may contribute, independently of
other factors, to VH among GPs for controversial vaccines. Past and on-
going controversies in Francemay have played— andmay still play— a
part in this distrust: the decision to suspend the school-based hepatitis
B vaccination program in 1998 (Larson and Heymann, 2010) and the
2009 pandemic vaccination campaign might have durably affected
GPs' trust in health authorities. The latter, in particular, excluded GPs
from its preparation and implementation (Schwarzinger et al., 2010),
a factor that negatively inﬂuenced their recommendations of the pan-
demic vaccine to patients (Verger et al., 2012; Flicoteaux et al., 2014).
Although discussing the causes of GPs' reduced or lack of trust toward
health authorities and experts is beyond the scope of this article, our re-
sults should prompt an in-depth reﬂection of how health authorities
communicate with private GPs and involve them in public health issues
such as vaccination.
Others have reported that physiciansmay have fears or doubts about
serious adverse effects of vaccines (François et al., 2011; Poland, 2010;
Verger et al., 2012; Daley et al., 2010), as we observed here. Our ﬁndings
suggest that these perceptions — probably reﬂecting sensitivity to vac-
cine controversies, as most of those in France have focused on vaccines'
side effects — contribute to VH among GPs, but only for controversial
vaccines (Table 3). Examining the pattern of these perceptions according
to each situation separately (Table 2) suggests that they reﬂect a dimen-
sion that is more attitudinal than evidence-based because we found that
the GPs' answers were not thoroughly consistent with the scientiﬁcevidence about vaccine adverse effects. GPs' negative perceptions of
aluminum as an adjuvant are not surprising in the French context: this
particular adjuvant has been the object of debate in France since 1998
when a group of French scientists published the ﬁrst of several articles
arguing that aluminum in vaccines can cause macrophagic myofasciitis
(localized lesions at the vaccination site, containing aluminum salts)
and long-term systemic adverse effects (Gherardi et al., 1998; Gherardi
et al., 2001; Couette et al., 2009). Both the WHO Global Advisory Com-
mittee on Vaccine Safety and the French Public Health Council, the latter
in a detailed scientiﬁc report in 2013 (Haut Conseil de la Santé Publique,
2013), agree that localized lesions occur in a small number of vaccine
patients, but ﬁnd no evidence to suggest that they are associated
with a resulting clinical illness or disease (Table A1, Appendix). This
controversy, essentially limited to France, has been simmering for
more than a decade, fuelled by one group of researchers and one asso-
ciation of patients and prolonged by the difﬁculty of proving negatives
and might well have contributed to the spread of doubts among French
doctors. Public health authorities and medical educators must ﬁnd ef-
fective strategies for addressing these attitudes among GPs.
Convincing vaccine-hesitant patients to be vaccinated requires a re-
sponse to GPs' VH. Necessary steps include both better training and
updating of GPs' knowledge of vaccines' beneﬁts and risks: more time
must be devoted to vaccination duringmedical studies than is currently
spent. Training should also aim at improving GPs' skills for communicat-
ing with vaccine-hesitant or reluctant patients. Initiatives such as the
guide “Let's talk about protection” can build the foundations for devel-
oping such approaches, but they have not been offered to doctors in
the ﬁeld of vaccination in France, as they have been elsewhere
(European Centre for Disease Prevention and Control, 2012). However,
these training tools andmethods should also be evaluated for effective-
ness. Finally, GPs and other doctors need supporting tools that provide
them with arguments to respond to allegations on the Internet or in
thenewsmedia: these tools should be regularly updated to newpercep-
tions and rumors. This would require the permanent monitoring of
various media, an approach that already exists in various ﬁelds due to
the progress of data mining technologies (Larson et al., 2013).
5. Research in Context
Our study of 1582 French GPs shows that they sometimes hesitate to
recommend vaccines against measles, hepatitis B, meningitis C, human
papilloma virus, or seasonal ﬂu to their patients for whom the health
authorities recommend them. This hesitancy is especially marked for
GPs who do not have conﬁdence in health authorities, who express
doubts about their harmlessness, do not feel comfortable explaining
the beneﬁts and risks of vaccines to patients, or are not convinced of
the general utility of vaccines. Given GPs' essential role in vaccination,
this may contribute to insufﬁcient coverage for these vaccines.
6. Conclusion
Overall our ﬁndings suggest that VH is prevalent among French GPs.
It maymake them ill at ease in addressing their patients' concerns about
vaccination, which in turn might reinforce patients' VH (Gowda and
Dempsey, 2013).
More research is warranted to assess VH among GPs and other
health care workers for an extended set of vaccines, target populations,
and countries. Better understanding of the determinants of VH among
physicians is also necessary, in particular to assess the extent to which
patients' VH contributes to physicians' VH (Peretti-Watel et al., 2015;
McRee et al., 2014). Our ﬁndings also call for the development and eval-
uation of interventions and tools targeting GPs to contain and restrain
their VH and help them cope with patients' VH. GPs would beneﬁt
from tools and training focusing on communication skills to address
their patients' concerns about vaccination (European Centre for Disease
Prevention and Control, 2012). Another important aspect lies in
897P. Verger et al. / EBioMedicine 2 (2015) 891–897addressing their distrust of the health authorities: this is not a simple
task, as it necessitates changes far beyond the vaccination ﬁeld.
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